A new role for SGLT2 inhibitors in the management of HFrEF
This webinar will discuss important new guideline updates regarding diagnosis and treatment optimisation for people with heart failure with reduced ejection fraction (HFrEF), including the role that sodium-glucose transport 2 inhibitors (SGLT2i) play in first-line management.

Click here for more information and to register.